CRD3874-SI
Various Cancers
Phase 1Active
Key Facts
About Curadev
Curadev is a private, clinical-stage biotechnology company founded in 2015, advancing a pipeline of novel small molecule drugs. Its lead asset, CRD3874-SI, is a first-in-class allosteric STING agonist in Phase 1 trials via a collaboration with Memorial Sloan Kettering Cancer Center. The company also has preclinical programs targeting STING antagonism, TNIK, and CLK/DYRK, supported by a leadership team with deep, long-standing relationships in drug discovery.
View full company profileOther Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| Oncology Immunotherapy Programs | Therapeutic Solutions International | Pre-clinical |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |